Intech Investment Management LLC Takes $152,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Intech Investment Management LLC acquired a new position in AngioDynamics, Inc. (NASDAQ:ANGO) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 16,540 shares of the medical instruments supplier’s stock, valued at approximately $152,000.

A number of other hedge funds also recently bought and sold shares of the company. Systematic Financial Management LP grew its stake in shares of AngioDynamics by 14.3% during the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after purchasing an additional 300,785 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in AngioDynamics by 69.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier’s stock valued at $3,564,000 after buying an additional 158,897 shares during the period. Royce & Associates LP grew its position in AngioDynamics by 13.5% during the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock valued at $10,254,000 after buying an additional 133,312 shares during the period. JPMorgan Chase & Co. raised its position in AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after acquiring an additional 123,271 shares during the period. Finally, Principal Financial Group Inc. bought a new position in AngioDynamics in the fourth quarter worth approximately $879,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.40% of the company’s stock.

AngioDynamics Trading Down 0.6 %

Shares of NASDAQ:ANGO opened at $9.83 on Friday. AngioDynamics, Inc. has a 12-month low of $5.47 and a 12-month high of $13.50. The company has a market cap of $397.78 million, a PE ratio of -1.75 and a beta of 0.56. The stock has a 50 day moving average of $10.47 and a 200 day moving average of $8.77.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the prior year, the company posted ($0.05) earnings per share. The company’s revenue for the quarter was down .1% compared to the same quarter last year. Equities research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.